SCHEMBL24253468

SCHEMBL24253468

Cc1cc(O)c(C)c(F)c1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.43
MAPT P10636 4/20 0.40
ALDH1A1 P00352 4/20 0.40
CYP3A4 P08684 3/20 0.40
KDM4E B2RXH2 3/20 0.40
HPGD P15428 2/20 0.40
ALOX15 P16050 2/20 0.40
MAPK1 P28482 2/20 0.40
HIF1A Q16665 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
G6PD P11413 1/20 0.40
CYP2C9 P11712 1/20 0.40
PKM P14618 1/20 0.40
ALOX12 P18054 1/20 0.40
CYP2C19 P33261 1/20 0.40
CCR6 P51684 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HSD17B10 Q99714 1/20 0.40
GAA P10253 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL251467 0.81 MAPT (0.42) ACHEMAPTALDH1A1CYP3A4KDM4E
SCHEMBL30413280 0.79 ACHE (0.43) ACHEMAPTALDH1A1CYP3A4KDM4E
SCHEMBL3687921 0.79 SELL (0.43) MAPTALDH1A1CYP3A4KDM4EHPGD
SCHEMBL374990 0.79 ACHE (0.43) ACHEMAPTALDH1A1CYP3A4KDM4E
SCHEMBL9670626 0.79 ACHE (0.43) ACHEMAPTALDH1A1CYP3A4KDM4E
SCHEMBL14783927 0.78 ALDH1A1 (0.45) ACHEMAPTALDH1A1CYP3A4KDM4E
SCHEMBL24253702 0.77 MAPK1 (0.36) MAPTALDH1A1CYP3A4KDM4EHPGD
SCHEMBL24874356 0.75 KDM4E (0.37) MAPTALDH1A1CYP3A4KDM4EHPGD
SCHEMBL2604714 0.75 CYP3A4 (0.30) ACHECYP3A4MAPK1TSHR
SCHEMBL24717973 0.74 ACHE (0.43) ACHEMAPTCYP3A4KDM4ENPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230069804-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-03-02 US disclosed
US-20220048890-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048890-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 ACHE 4547/4885MAPT 1932/4885ALDH1A1 3964/4885
US-20230069804-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 ACHE 4547/4885MAPT 1932/4885ALDH1A1 3964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.